Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Issue : The Pharmaceutical Journal, 21/28 June 2014, Vol 292, No 7815/6

Sort by: Newest first Oldest first A-Z Z-A

  • Local practice forum meeting, North East of Scotland Subscription

    21 JUN 2014 0:00

    “Royal Pharmaceutical Society guidance — improving patient outcomes the better use of multi-compartment compliance aids and supporting change.”

  • Local practice forum meeting, Jersey Subscription

    21 JUN 2014 0:00

    “Meet and greet with local members of the Royal Pharmaceutical Society.” Find out more about what the RPS can do for you and how you can be involved in developing the Jersey LPF.  

  • Local practice forum meeting, West Central Scotland (Glasgow) Subscription

    21 JUN 2014

    Premier Inn, Glasgow City Centre George Square, 187 George Street, Glasgow G1 1YU. Meeting 7pm

  • Local practice forum meeting, Sussex Subscription

    21 JUN 2014 0:00

    “Bridging the gap — transfer of care project, the future,” by Zoe Girdis and Megan Hockly. 

  • Anne Catherine Anderson dies Subscription

    21 JUN 2014 0:00

    Mrs Anderson registered in 1953, became a Fellow in 1992 and left the Society in 2004

  • A tribute to John Richardson Subscription

    21 JUN 2014 0:00

    In tribute to the late John Richardson (PJ, 7 June 2014, p589), MIALL E JAMES, FRPharmS, writes

  • Synacten Subscription

    21 JUN 2014

    The updated summary of product characteristics for Synacten (tetracoside acetate; Alliance) now states that the risks of treatment should be weighed against the benefits if patients have one of the following conditions: ulcerative colitis, diverticulitis, recent intestinal anastomosis, kidney failure, hypertension, predisposition to thromboembolism, osteoporosis, myasthenia gravis.

  • Lucentis Subscription

    21 JUN 2014

    Lucentis (ranibizumab) is now available in a pre-filled syringe from Novartis. Lucentis vials will continue to be available. Net price, 1 x syringe, £742.17.  

  • Otosporin ear drops Subscription

    21 JUN 2014

    GlaxoSmithKline has discontinued Otosporin (hydrocortisone, polymyxin B sulphate, neomycin sulphate) ear drops in the UK because of manufacturing complexities. Further information is available on 0800 221 441.

  • Budenofalk Subscription

    21 JUN 2014

    Budesonide gastro-resistant granules (Budenofalk) have been accepted for use within NHS Scotland by the Scottish Medicines Consortium (SMC). The approved indication is the induction of remission in patients with mild to moderate active Crohn’s disease affecting the ileum or ascending colon or both. Defibrotide (Defitelio), for the treatment of severe hepatic veno-occlusive disease, and fluticasone furoate and vilanterol (Relvar Ellipta), for the regular treatment of asthma in adults ...

Show  10 per page20 per page50 per page

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.